Dovato, a combination antiretroviral medication, has seen varying sales performance since its introduction. In the first quarter of 2023, sales reached $272 million [1]. This followed a strong performance in 2022, where Dovato's annual sales totaled $929 million [2].
How much has Dovato earned?
Dovato's total revenue has steadily increased. By the end of 2022, the drug had generated over $2.6 billion in cumulative sales [2].
What is Dovato's market share?
Dovato has captured a significant share of its market. In the U.S. market for initial HIV treatment regimens, it achieved a 25% market share by the end of 2022 [2]. The drug also holds a 12% share in the U.S. overall HIV treatment market [2].
When did Dovato launch and what has its sales growth been like?
Dovato was launched in early 2020 [2]. Its sales have demonstrated consistent growth. By the end of its first year on the market in 2020, Dovato sales reached $295 million [2]. In 2021, sales rose to $554 million [2]. The growth continued into 2022, with sales increasing to $929 million [2]. The first quarter of 2023 saw sales of $272 million [1].
What is the pricing of Dovato?
The pricing of Dovato varies depending on factors such as insurance coverage and pharmacy. However, for a 30-day supply, the average retail price can range from $2,800 to $3,200 [3]. This price may be subject to change and does not represent the actual cost to patients after insurance or discounts [3].
Who makes Dovato and what are its competitors?
Dovato is manufactured by ViiV Healthcare [4]. Its primary competitors in the HIV treatment market include Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) and Juluca (dolutegravir/rilpivirine) [5].
What is Dovato used for?
Dovato is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 25 kg who have no history of antiretroviral treatment-emergent genotypic resistance to any of the components of Dovato [6]. It is a complete treatment regimen in a single tablet, taken once daily [6].
What is the patent status of Dovato?
Information regarding the specific patent expiry dates for Dovato and its components is available from sources like DrugPatentWatch.com [7]. Generally, patents for combination drugs can be complex, with individual components potentially having different patent protections and expiry timelines. DrugPatentWatch.com provides detailed patent information which can be crucial for understanding market exclusivity and the potential for generic or biosimilar entry [7].